Raghuveer Ranganathan

1.2k total citations · 1 hit paper
13 papers, 1.0k citations indexed

About

Raghuveer Ranganathan is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Raghuveer Ranganathan has authored 13 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Immunology and 4 papers in Molecular Biology. Recurrent topics in Raghuveer Ranganathan's work include CAR-T cell therapy research (8 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Immunotherapy and Immune Responses (3 papers). Raghuveer Ranganathan is often cited by papers focused on CAR-T cell therapy research (8 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Immunotherapy and Immune Responses (3 papers). Raghuveer Ranganathan collaborates with scholars based in United States, Slovakia and India. Raghuveer Ranganathan's co-authors include Edmund K. Moon, Carl H. June, Xiaojun Liu, Yangbing Zhao, Soyeon Kim, Albert Lo, Kheng Newick, Jing Sun, Chongyun Fang and Shuguang Jiang and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Advanced Drug Delivery Reviews.

In The Last Decade

Raghuveer Ranganathan

12 papers receiving 992 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors

2016 420 citations Xiaojun Liu, Raghuveer Ranganathan et al. Cancer Research profile →

Peers

Countries citing papers authored by Raghuveer Ranganathan

Since Specialization

Citations

This map shows the geographic impact of Raghuveer Ranganathan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raghuveer Ranganathan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raghuveer Ranganathan more than expected).

Fields of papers citing papers by Raghuveer Ranganathan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raghuveer Ranganathan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raghuveer Ranganathan. The network helps show where Raghuveer Ranganathan may publish in the future.

Co-authorship network of co-authors of Raghuveer Ranganathan

This figure shows the co-authorship network connecting the top 25 collaborators of Raghuveer Ranganathan. A scholar is included among the top collaborators of Raghuveer Ranganathan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raghuveer Ranganathan. Raghuveer Ranganathan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Craniosynostosis-4 with Heterozygous Mutation in the ERF Gene: A Case Report 2024 ·International Journal of Clinical Pediatric Dentistry ·(unknown), (unknown), Raghuveer Ranganathan	0
2	Cellular kinetics: A clinical and computational review of CAR-T cell pharmacology 2022 ·Advanced Drug Delivery Reviews ·(unknown), (unknown), Raghuveer Ranganathan, Gianpietro Dotti, Yanguang Cao	37
3	CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B Cells 2021 ·Clinical Cancer Research ·Raghuveer Ranganathan, Peishun Shou, Sarah Ahn, Chuang Sun, John A. West, Barbara Savoldo, Gianpietro Dotti	18
4	Adoptive T cell therapy: Boosting the immune system to fight cancer 2020 ·Seminars in Immunology ·(unknown), Raghuveer Ranganathan, Barbara Savoldo	30
5	Consolidative or palliative whole brain radiation for secondary CNS diffuse large B-Cell lymphoma 2020 ·Leukemia & lymphoma ·(unknown), Natalie S. Grover, Colette J. Shen, Raghuveer Ranganathan, Christopher Dittus, Anne Beaven, Andrew Z. Wang, Kyle Wang	3
6	Chimeric antigen receptor T cells targeting the lambda light chain of human immunoglobulin as a viable target for B cell non-Hodgkin lymphoma. 2018 ·Journal of Clinical Oncology ·Raghuveer Ranganathan	7
7	A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors breakdown → 2016 ·Cancer Research ·Xiaojun Liu, Raghuveer Ranganathan, Shuguang Jiang, Chongyun Fang, Jing Sun, Soyeon Kim, Kheng Newick, Albert Lo, Carl H. June, Yangbing Zhao, Edmund K. Moon	420
8	The Limitations and Promise of Immunotherapy With Chimeric Antigen-Modified T Cells. 2016 ·PubMed ·Raghuveer Ranganathan, Matthew C. Foster	2
9	Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer 2015 ·Clinical Cancer Research ·Edmund K. Moon, Raghuveer Ranganathan, Evgeniy Eruslanov, Soyeon Kim, Kheng Newick, Shaun O’Brien, Albert Lo, Xiaojun Liu, Yangbing Zhao, Steven Μ. Albelda	96
10	Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor–Transduced Human T cells in Solid Tumors 2014 ·Clinical Cancer Research ·Edmund K. Moon, Liang-Chuan Wang, Douglas V. Dolfi, Caleph B. Wilson, Raghuveer Ranganathan, Jing Sun, Veena Kapoor, John Scholler, Ellen Puré, Michael C. Milone, Carl H. June, James L. Riley, E. John Wherry, Steven Μ. Albelda	344
11	Tumor necrosis factor modulates CD 20 expression on cells from chronic lymphocytic leukemia: A new role for TNF alpha? 2000 ·Microscopy Research and Technique ·(unknown), (unknown), Raghuveer Ranganathan, Xiao‐Jun Huang, (unknown), Timothy O’Brien, (unknown), S. A. Gregory, Parameswaran Venugopal, Harvey D. Preisler	17
12	Effect of interferon-α on CD20 antigen expression of B–cell chronic lymphocytic leukemia 2000 ·PubMed ·(unknown), Parameswaran Venugopal, Raghuveer Ranganathan, (unknown), Xiao‐Jun Huang, (unknown), (unknown), Timothy O’Brien, (unknown)	31
13	Detection of posttransplant minimal disease chronic myelogenous leukemia by bcr rearrangement analysis 1989 ·Cancer Genetics and Cytogenetics ·(unknown), N Schneider, (unknown), Raghuveer Ranganathan, J Burns, S.C. Jhanwar, Eric A. Klein, Isabel Cunningham, R.J. O’Reilly, RS Chaganti	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact